Cellular Dynamics International Inc. is using induced pluripotent stem (iPS) cells, derived from adult cells, as drug discovery and development tools. The company is initially pursuing the cardiotoxicity market with iCell cardiomyocytes, which closely resemble in vivo cardiomyocytes, even beating in unison in a cell culture dish. When exposed to drugs or other external agents, the cells produce electrophysiological and biochemical responses typical of in vivo cardiomyocytes.
525 Science Drive
Madison, WI 53711
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Data presented at the Berlin meeting highlight the potential of the company's cell therapy anzu-cel to redefine the treatment paradigm for uveal melanoma.
The drugmaker is joining the rush to acquire an in vivo CAR-T therapy developer as concerns mount about whether the health care system can accommodate cell therapies’ dramatic growth.
While some big pharma companies have exited cell and gene therapy, Novartis, Astellas, Gilead’s Kite and AstraZeneca’s Alexion are diving back in, executives said at ARM’s Cell and Gene Meeting on the Mesa.
While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.
The Basel-based company has faith in its existing rare disease commercial platform to successfully market the newly-acquired assets.
The drugmaker has made numerous moves in the field this year, with the latest deal bringing in ixo-vec, a Phase III candidate for wet AMD.
Data presented at the Berlin meeting highlight the potential of the company's cell therapy anzu-cel to redefine the treatment paradigm for uveal melanoma.
